Key result
This review highlights the clinical and economic ramifications of premature discontinuation of dual antiplatelet therapy following percutaneous coronary intervention and discusses strategies for improvement.
Why the study?
How can adherence to dual antiplatelet therapy be improved in patients following percutaneous coronary intervention?
How can adherence to dual antiplatelet therapy be improved in patients following percutaneous coronary intervention?
This review highlights the critical need for improved management strategies to ensure adherence to dual antiplatelet therapy after percutaneous coronary intervention.
Alerts to clinical and economic risks of premature DAPT discontinuation post-PCI; leaves open optimal adherence strategies.
Management strategies to ensure medication adherence for patients following percutaneous coronary intervention have not changed in recent years despite the dismal rates of non-compliance with dual antiplatelet therapy. The goal of this review is to emphasis the importance of dual antiplatelet therapy in patients following percutaneous coronary intervention, discuss the clinical and economic ramifications of premature discontinuation and strategies for improvement.
No takes yet. Share an insight, caveat, or question.
Yallapragada et al. (2013) conducted a review in Percutaneous coronary intervention. Dual antiplatelet therapy was evaluated. This review highlights the clinical and economic ramifications of premature discontinuation of dual antiplatelet therapy following percutaneous coronary intervention and discusses strategies for improvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: